Ceapro inc. announces the appointment of Geneviève Foster to the Board of Directors


EDMONTON, Alta., April 19, 2022 (GLOBE NEWSWIRE) — Ceapro Inc.(TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”)a growth-stage biotechnology company focused on the development and commercialization of active ingredients for the health and cosmetics industries, today announced the appointment of Geneviève Foster to its Board of Directors.

Ms. Foster is an established businesswoman, lawyer and corporate executive with experience in multiple industries, including life sciences and pharmaceuticals. During her career, she has negotiated several value-creating transactions, including joint ventures, licensing agreements, R&D agreements and equity financings for public and private companies.

“As a new independent director with expertise in governance, knowledge of law and international business development, Ms. Foster is an excellent addition to our Board of Directors. I believe her depth and breadth of experience is a valuable contribution and we look forward to working with her to help propel Ceapro into its next phase of growth,” commented Glenn R. Rourke, Chairman of the Board. from Ceapro.

“I see significant potential in Ceapro. The team has done a great job establishing a core business and leveraging its proprietary technologies to grow and scale into nutraceuticals and pharmaceuticals. I am dedicated to contributing to the success of this growing company and to leveraging the expertise I have gained over my career. I look forward to working closely with the management team to unlock additional potential and value for Ceapro,” added Ms. Foster.

Since 2008, Ms. Foster has run her own legal practice where she provides legal services to private SMEs and public companies, including companies in the pharmaceutical and life sciences industry. Previously, she was Vice President, Legal Affairs and Corporate Secretary at Warnex Inc., a Toronto Stock Exchange listed company that developed and licensed innovative technologies and operated medical and pharmaceutical laboratories. Other professional appointments include Director, Legal Affairs and Corporate Secretary of Boomerang Tracking Inc., a Toronto Stock Exchange-listed company that used cellular technology to track stolen vehicles, and Spectra Telecom ST Inc., a subsidiary of SNC-Lavalin and Telesystem in the field of engineering and construction. of wireless telecommunications towers on the international stage. From 1996 to 1999, Me Foster was a business lawyer at Langlois Gaudreau. Ms. Foster currently sits on the board of directors of the Quebec CPA Order and of Oxfam Quebec. Previously, she sat on the board of directors and management of BioQuébec.

“We are pleased to welcome Geneviève to our Board of Directors. His diverse industry expertise and successful experience negotiating strategic transactions throughout his career provide valuable perspective as we continue to evolve Ceapro. The operational skills she has acquired over her career align perfectly with our strategic goals and initiatives and she is a welcome addition to the team,” concluded Gilles Gagnon, M.Sc., MBA, President and Chief Executive Officerfrom Ceapro.

With her appointment to the Board of Directors, Ms. Foster was granted options to obtain 150,000 common shares of Ceapro, each with an exercise price according to TSX-V regulations. Each grant vests in three equal installments, the first of which vests immediately and the second and third installments vest on the first and second anniversaries of the grant date. Each option is exercisable, once vested, for a period of five years from the date of grant.

About Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds additional value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutic products for humans and animals. The Company has a wide range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug delivery solutions. For more information about Ceapro, please visit the company’s website at www.ceapro.com.

For more information contact:

jenene thomas
Investor Relations and Corporate Communication Advisor
T (US): +1 (833) 475-8247
E: [email protected]

Transmitter :
Gilles R. Gagnon, M.Sc., MBA
President and CEO
Such. : 780-421-4555

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

main logo


Comments are closed.